FDAsafety guidance66% confidence
FDA AP — TRYNGOLZA (AUTOINJECTOR) (SUPPL)
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for AstraZeneca; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application NDA218614. Sponsor: IONIS PHARMS INC. Submission status: AP. Submission type: SUPPL. Review priority: PRIORITY. Active ingredients: OLEZARSEN SODIUM.
Supporting Context
- Therapeutic area
- Neurology · RNA-targeted therapy
- Sub-indication
- General
Related signal: FDA Accepts Supplemental Application for WAINUA Autoinjector by AstraZeneca